￥ 人民币 $ USD € 欧元
简体中文 English 繁体中文
028-123456789
Menu

Oncology

Gitarel can treat non-small cell lung cancer with EGFR gene mutations and lung squamous cell carcinoma with disease progression after chemotherapy

2025-10-19 11:44:20

Check Details
Gitari has good efficacy in treating lung squamous cell carcinoma

2025-10-19 11:44:20

Check Details
Effect data of XL184 in patients with RET-rearranged lung cancer

2025-10-19 11:44:20

Check Details
Gyterin is the first targeted drug that can significantly improve the overall survival of patients with common EGFR mutations compared with chemotherapy_ Kanghule

2025-10-19 11:44:20

Check Details
The role of broad-spectrum anticancer drug XL184 in RET-rearranged lung cancer

2025-10-19 11:44:20

Check Details
Giterinib (afatinib) can significantly extend the progression-free survival of patients with brain metastases compared with chemotherapy_ Kanghule

2025-10-19 11:44:20

Check Details
The efficacy of Giterinib (afatinib) in second-line lung squamous cell carcinoma patients is significantly better than that of first-generation TKI_ Kanghule

2025-10-19 11:44:20

Check Details
Where can I buy lung cancer drug XL184? What's the price?

2025-10-19 11:44:20

Check Details
Can XL184 be used to treat patients with MET14 mutated lung cancer?

2025-10-19 11:44:20

Check Details
Gitari can effectively reduce the risk of death and disease progression in advanced squamous non-small cell lung cancer

2025-10-19 11:44:20

Check Details
The emergence of Gitari gives patients with lung squamous cell carcinoma an additional choice

2025-10-19 11:44:20

Check Details
Dosage of anti-cancer drug XL184 for lung cancer

2025-10-19 11:44:20

Check Details
Category
相关知识